Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| The PATH Malaria Vaccine Initiative (MVI) | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
This epidemiology study was conducted in parallel with the EPI-MAL-002 (NCT02374450) and EPI-MAL-003 (NCT03855995) studies, enrolling participants from the same health and demographic surveillance system (HDSS) (or equivalent system) populations. The co-primary objectives were to produce longitudinal estimates of parasite prevalence in humans and to record the usage of malaria control measures in areas where the EPI-MAL-002 and EPI-MAL-003 studies were conducted.
This study involved 10 annual cross-sectional surveys conducted during malaria peak transmission seasons. The surveys provided point estimates of parasite prevalence and subsequently enabled a longitudinal assessment of the level of endemicity in each area covered by EPI-MAL-002 and EPI-MAL-003. The study was conducted in parallel with EPI-MAL-002 and EPI-MAL-003 to assess parasite prevalence and malaria control measures before (EPI-MAL-002) and after (EPI-MAL-003) vaccine introduction.
By taking into account variations in malaria transmission intensity (MTI) and malaria control intervention coverage, it enabled a more complete assessment of the benefits and risks of the vaccine introduction, and thereby provided greater insight into the potential vaccine impact in EPI-MAL-002/-003 by adjusting incidence data for overall changes in transmission and other malaria control intervention coverage, and assisted in the generalisation of results to other populations.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Survey 1 Group | Other | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 1. |
|
| Survey 2 Group | Other | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 2. |
|
| Survey 3 Group | Other | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 3. |
|
| Survey 4 Group | Other | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 4. |
|
| Survey 5 Group | Other | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 5. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Assessment of body temperature | Diagnostic Test | Axillary body temperature of all participants recorded by a digital thermometer at the time of survey. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants Infected With Plasmodium Falciparum (P. Falciparum) by World Health Organisation (WHO) Age Group | The number of participants was summarized by the WHO age group (0.5-1 year [Y] and 2-9Y) and by center number/ country [Burkina Faso (BF), Senegal (SN), Tanzania (TZ), Kenya (KE), Ghana (GH), Malawi (MA)]/ city. Unexposed (UNEXP) sites are the ones in which the RTS,S vaccine was not planned to be implemented during the course of the study however, vaccinated participants could still have been randomly selected in this population if vaccination happened in an exposed (EXP) site, due to cross-site migration. The infection was identified using a blood smear slide and determined using microscopy. | At Day 1 (survey completion visit) |
| Number of Participants Infected With P. Falciparum by Joint Technical Expert Group (JTEG) Age Group | The number of participants was summarized by the JTEG age group (0.5-4Y and 5-9Y) by center number/ country [BF, SN, TZ, KE, GH, MA]/ city. UNEXP sites are the ones in which the RTS,S vaccine was not planned to be implemented during the course of the study however, vaccinated participants could still have been randomly selected in this population if vaccination happened in an EXP site, due to cross-site migration. The infection was identified using a blood smear slide and determined using microscopy. | At Day 1 (survey completion visit) |
| Number of Participants Using Malaria Control Interventions: Bednet Usage and Type of Bednet | The number of participants using malaria control interventions was summarized by: participants sleeping under a mosquito net the night before their visit, participants who have a new bednet (less than 1 year), participants who have a impregnated bednet (dipped in liquid to repel mosquitos after purchase), participants who have a pierced/torn bednet, participants with bednets classified by hole size (defined as holes big enough to let one finger go through) and number of holes (less than [<] 5 holes, more or equal [>=] to 5 holes, not applicable [NA] which is a participant who did not sleep under a bed net, missing confirmed [MC] which is a participant who slept under a mosquito net but who didn't answer to the question on holes). |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants Infected With P. Falciparum by Center, Gender and Infection Status | The number of participants was summarized by: center number/ country [BF, SN, TZ, KE, GH, MA]/ city, gender (female, male) and infection status (infected, not infected). | At Day 1 (survey completion visit) |
| Number of Participants Infected With Plasmodium Species Other Than P. Falciparum |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| GSK Clinical Trials | GlaxoSmithKline | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| GSK Investigational Site | Nouna | Burkina Faso | ||||
| GSK Investigational Site |
GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About\_GSK\_Patient\_Level\_Data\_Sharing\_Final\_13July2023.pdf.
Not provided
Not provided
Not provided
Not provided
Out of 54115 participants enrolled, 54100 participants were included in the Total Effective Cohort and started the study.
Participants were enrolled from Health and Demographic Surveillance System (HDSS) (or equivalent system) catchment areas at the sites participating in the EPI-MAL-002 (NCT02374450) and EPI-MAL-003 (NCT03855995) studies of the candidate malaria vaccine RTS,S/AS01E in sub-Saharan Africa.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Survey 1 Group | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 1. |
| FG001 | Survey 2 Group | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 2. |
| FG002 | Survey 3 Group | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 3. |
| FG003 | Survey 4 Group | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 4. |
| FG004 | Survey 5 Group | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 5. |
| FG005 | Survey 6 Group | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 6. |
| FG006 | Survey 7 Group | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 7. |
| FG007 | Survey 8 Group | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 8. |
| FG008 | Survey 9 Group | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 9. |
| FG009 | Survey 10 Group | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 10. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
The Baseline analysis was performed on the Total Effective Cohort, which included all participants enrolled in the study for whom data was collected.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Survey 1 Group | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 1. |
| BG001 | Survey 2 Group |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | The Age Continuous analysis was based on participants' age recorded at the time of signing the Informed Consent Form (ICF). |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants Infected With Plasmodium Falciparum (P. Falciparum) by World Health Organisation (WHO) Age Group | The number of participants was summarized by the WHO age group (0.5-1 year [Y] and 2-9Y) and by center number/ country [Burkina Faso (BF), Senegal (SN), Tanzania (TZ), Kenya (KE), Ghana (GH), Malawi (MA)]/ city. Unexposed (UNEXP) sites are the ones in which the RTS,S vaccine was not planned to be implemented during the course of the study however, vaccinated participants could still have been randomly selected in this population if vaccination happened in an exposed (EXP) site, due to cross-site migration. The infection was identified using a blood smear slide and determined using microscopy. | The analysis was performed on the According To Protocol (ATP) Cohort which included all participants who met the eligibility criteria, adhered to the procedures defined in the protocol, had no elimination criteria during the study, had at least one laboratory result from a blood sample available and with usable data for the specified analysis at the specified time point. Here, 'number analyzed' = participants with available data for each specified row. | Posted | Count of Participants | Participants | At Day 1 (survey completion visit) |
Serious adverse events (SAEs) and all-cause mortality were collected from Year 1 to Year 10
According to the pre-specified protocol, only serious adverse events were collected. Since no other adverse events were captured in this study, the total number of participants at risk or affected by non-serious adverse events is zero. The analysis was performed on the Total Effective Cohort.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Survey 1 Group | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 1. |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| GSK Response Center | GlaxoSmithKline | 866-435-7343 | GSKClinicalSupportHD@gsk.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Sep 14, 2018 | Jul 4, 2025 | Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Apr 8, 2020 | Jul 4, 2025 | SAP_001.pdf |
Not provided
| ID | Term |
|---|---|
| D008288 | Malaria |
| D016778 | Malaria, Falciparum |
| ID | Term |
|---|---|
| D011528 | Protozoan Infections |
| D010272 | Parasitic Diseases |
| D007239 | Infections |
| D000096724 | Mosquito-Borne Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D001800 | Blood Specimen Collection |
| ID | Term |
|---|---|
| D013048 | Specimen Handling |
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Survey 6 Group | Other | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 6. |
|
| Survey 7 Group | Other | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 7. |
|
| Survey 8 Group | Other | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 8. |
|
| Survey 9 Group | Other | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 9. |
|
| Survey 10 Group | Other | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 10. |
|
| Blood sampling | Procedure | Capillary blood samples collected by finger/heel prick for determination of parasite prevalence at the time of survey. |
|
| At Day 1 (survey completion visit) |
| Number of Participants Using Malaria Control Interventions: Mosquito Coils, Insecticide Sprays, Commercial Repellants, Traditional Repellants and Indoor Residual Sprays | The number of participants using malaria control interventions was summarized by: mosquito coils, insecticide sprays, commercial repellants, traditional repellants and indoor residual sprays (in the past 12 months, 1 to 12 months, NA [the participant didn't use the residual spray], missing [participant used spray but didn't answer to how long ago]). | At Day 1 (survey completion visit) |
The infections with other Plasmodium species were determined using a blood smear slide and microscopy. The number of participants infected with P. malaria, P. vivax and P. ovale was summarized. |
| At Day 1 (survey completion visit) |
| Number of Participants Who Received Dose 3 of the Diphtheria, Tetanus, Pertussis/ Hepatitis B/ Haemophilus Influenzae Type b (DTP/HepB/Hib) Vaccine or Dose 1 of the Measles Vaccine | At Day 1 (survey completion visit) |
| Number of Participants Who Received Anti-malarial Therapy or Any Other Medication Within 14 Days Prior to the Study Visit | The number of participants who received anti-malarial therapy out of those who reported malaria in the last 14 days prior to the study visit was summarized. | Up to 14 days prior to the study visit at Day 1 |
| Number of Participants With Measured Fever at the Time of Their Study Visit | Fever was defined as an axillary temperature of 37.5°C or higher. | At Day 1 (survey completion visit) |
| Number of Participants With Reported Fever in the 24 Hours Prior to Their Study Visit | Fever was defined as an axillary temperature of 37.5°C or higher. | Up to 24 hours prior to their study visit at Day 1 |
| Number of Participants Demonstrating Care-seeking Behavior Following Reported Fever or Malaria up to 14 Days Prior to Their Study Visit | The number of participants demonstrating care-seeking behavior following reported fever or malaria was summarized by where the participant was taken for treatment (home, drug seller, pharmacy, private clinic, health center, hospital, other, not applicable [no treatment received]), by when the participant was taken for treatment (at onset, when the participant did not improve, when the participant got worse, other, not applicable [no treatment received], missing [participant was taken for treatment but did not answer the question regarding when]) and by what time the participant was taken for treatment (the same day, the next day, 2 days later, more than 2 days later, not applicable [no treatment received], missing [participant was taken for treatment but did not answer the question regarding the time]). | Up to 14 days prior to their study visit at Day 1 |
| Number of Participants in Each Geo-referenced Segment | The number of participants was summarized by: center number/ country [BF, SN, TZ, KE, GH, MA]/ city followed by the segment ID. Positioning of the participant's residence was attributed to a segment with a unique ID from the grid referencing study area map in which the participant resided; where necessary, grouping small geographically proximate villages so that each segment had at least 10 study participants to avoid personally identifiable information (PII), and proceeding as far as geographically appropriate. | At Day 1 (survey completion visit) |
| Number of Participants Experiencing Malaria Risk Factors Categorized by the Number of Participants Living in the Same House (by Parasite Density) | Participants were categorized by the number of people living in the same house relative to enrolled participants as follows: less than of equal to (<=) 3 per 1 enrolled (LE 3/1), 4-5 per 1 (4-5/1), more than (>) 5 per 1 (GT 5/1); <=3 per 2 enrolled (LE 3/2), 4-5 per 2 (4-5/2), >5 per 2 (GT 5/2); <=3 per 3 enrolled (LE 3/3), 4-5 per 3 (4-5/3), >5 per 3 (GT 5/3); 4-5 per more than 3 enrolled (4-5/GT 3), >5 per more than 3 enrolled (GT 5/GT 3). Participants were also categorized by parasite density: low (<2500 parasites/μL), medium (2500-9999/μL), high (10000-19999/μL), very high (>=20000/μL), negative, and missing. | At Day 1 (survey completion visit) |
| Number of Participants Experiencing Malaria Risk Categorized by Location (by Parasite Density) | Participants were categorized by location as follows: situation area (rural, urban, semi-rural) and type of location (large city, small city, town, countryside). Participants were also categorized by parasite density: low (<2500 parasites/μL), medium (2500-9999/μL), high (10000-19999/μL), very high (>=20000/μL), negative, and missing. | At Day 1 (survey completion visit) |
| Number of Participants Experiencing Malaria Risk Factors Categorized by House Information (by Parasite Density) | Participants were categorized by house characteristics as follows: wall material (mud, brick, cement/plaster, clay, other), floor material (natural, rudimentary, vinyl/asphalt strips, parquet/polished wood, ceramic tiles, cement, carpet, clay, other), roof type (iron sheet, tiles, clay, other), window type (closed, open, no window, partially open, other), presence of nets (not present, present on all windows, present on some windows, other, missing), main drinking water source (closed, open), whether the open source was in the compound (yes, no, not available [NA]), and presence or absence of electricity. Participants were also categorized by parasite density: low (<2500 parasites/μL), medium (2500-9999/μL), high (10000-19999/μL), very high (>=20000/μL), negative, and missing. | At Day 1 (survey completion visit) |
| Ouagadougou |
| 2208 |
| Burkina Faso |
| GSK Investigational Site | Kintampo | Ghana |
| GSK Investigational Site | Navrongo | Ghana |
| GSK Investigational Site | Kisumu | 40100 | Kenya |
| GSK Investigational Site | Kisumu | 40102 | Kenya |
| GSK Investigational Site | Nairobi | 40100 | Kenya |
| GSK Investigational Site | Chikwawa | Malawi |
| GSK Investigational Site | Mangochi | Malawi |
| GSK Investigational Site | Dakar | 12500 | Senegal |
| GSK Investigational Site | Dakar | 16556 | Senegal |
| GSK Investigational Site | Amani | Tanzania |
Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 2.
| BG002 | Survey 3 Group | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 3. |
| BG003 | Survey 4 Group | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 4. |
| BG004 | Survey 5 Group | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 5. |
| BG005 | Survey 6 Group | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 6. |
| BG006 | Survey 7 Group | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 7. |
| BG007 | Survey 8 Group | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 8. |
| BG008 | Survey 9 Group | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 9. |
| BG009 | Survey 10 Group | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 10. |
| BG010 | Total | Total of all reporting groups |
The Age Continuous analysis is presented separately for each of the 10-survey year. |
| Mean |
| Standard Deviation |
| Years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race and Ethnicity Not Collected | Race and Ethnicity were not collected from any participant. | Count of Participants | Participants |
|
| ID | Title | Description |
|---|---|---|
| OG000 | Survey 1 Group | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 1. |
| OG001 | Survey 2 Group | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 2. |
| OG002 | Survey 3 Group | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 3. |
| OG003 | Survey 4 Group | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 4. |
| OG004 | Survey 5 Group | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 5. |
| OG005 | Survey 6 Group | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 6. |
| OG006 | Survey 7 Group | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 7. |
| OG007 | Survey 8 Group | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 8. |
| OG008 | Survey 9 Group | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 9. |
| OG009 | Survey 10 Group | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 10. |
|
|
| Secondary | Number of Participants Infected With P. Falciparum by Center, Gender and Infection Status | The number of participants was summarized by: center number/ country [BF, SN, TZ, KE, GH, MA]/ city, gender (female, male) and infection status (infected, not infected). | The analysis was performed on the ATP Cohort which included all participants who met the eligibility criteria, adhered to the procedures defined in the protocol, had no elimination criteria during the study, had at least one laboratory result from a blood sample available and with usable data for the specified analysis at the specified time point. Here, 'number analyzed' = participants with available data for each specified row. | Posted | Count of Participants | Participants | At Day 1 (survey completion visit) |
|
|
|
| Secondary | Number of Participants Infected With Plasmodium Species Other Than P. Falciparum | The infections with other Plasmodium species were determined using a blood smear slide and microscopy. The number of participants infected with P. malaria, P. vivax and P. ovale was summarized. | The analysis was performed on the ATP Cohort which included all participants who met the eligibility criteria, adhered to the procedures defined in the protocol, had no elimination criteria during the study, had at least one laboratory result from a blood sample available and with usable data for the specified analysis at the specified time point. | Posted | Count of Participants | Participants | At Day 1 (survey completion visit) |
|
|
|
| Secondary | Number of Participants Who Received Dose 3 of the Diphtheria, Tetanus, Pertussis/ Hepatitis B/ Haemophilus Influenzae Type b (DTP/HepB/Hib) Vaccine or Dose 1 of the Measles Vaccine | The analysis was performed on the ATP Cohort which included all participants who met the eligibility criteria, adhered to the procedures defined in the protocol, had no elimination criteria during the study, had at least one laboratory result from a blood sample available and with usable data for the specified analysis at the specified time point. | Posted | Count of Participants | Participants | At Day 1 (survey completion visit) |
|
|
|
| Secondary | Number of Participants Who Received Anti-malarial Therapy or Any Other Medication Within 14 Days Prior to the Study Visit | The number of participants who received anti-malarial therapy out of those who reported malaria in the last 14 days prior to the study visit was summarized. | The analysis was performed on the ATP Cohort which included all participants who met the eligibility criteria, adhered to the procedures defined in the protocol, had no elimination criteria during the study, had at least one laboratory result from a blood sample available and with usable data for the specified analysis for the specified time period. | Posted | Count of Participants | Participants | Up to 14 days prior to the study visit at Day 1 |
|
|
|
| Secondary | Number of Participants With Measured Fever at the Time of Their Study Visit | Fever was defined as an axillary temperature of 37.5°C or higher. | The analysis was performed on the ATP Cohort which included all participants who met the eligibility criteria, adhered to the procedures defined in the protocol, had no elimination criteria during the study, had at least one laboratory result from a blood sample available and with usable data for the specified analysis at the specified time point. | Posted | Count of Participants | Participants | At Day 1 (survey completion visit) |
|
|
|
| Secondary | Number of Participants With Reported Fever in the 24 Hours Prior to Their Study Visit | Fever was defined as an axillary temperature of 37.5°C or higher. | The analysis was performed on the ATP Cohort which included all participants who met the eligibility criteria, adhered to the procedures defined in the protocol, had no elimination criteria during the study, had at least one laboratory result from a blood sample available and with usable data for the specified analysis for the specified time period. | Posted | Count of Participants | Participants | Up to 24 hours prior to their study visit at Day 1 |
|
|
|
| Secondary | Number of Participants Demonstrating Care-seeking Behavior Following Reported Fever or Malaria up to 14 Days Prior to Their Study Visit | The number of participants demonstrating care-seeking behavior following reported fever or malaria was summarized by where the participant was taken for treatment (home, drug seller, pharmacy, private clinic, health center, hospital, other, not applicable [no treatment received]), by when the participant was taken for treatment (at onset, when the participant did not improve, when the participant got worse, other, not applicable [no treatment received], missing [participant was taken for treatment but did not answer the question regarding when]) and by what time the participant was taken for treatment (the same day, the next day, 2 days later, more than 2 days later, not applicable [no treatment received], missing [participant was taken for treatment but did not answer the question regarding the time]). | The analysis was performed on the ATP Cohort which included all participants who met the eligibility criteria, adhered to the procedures defined in the protocol, had no elimination criteria during the study, had at least one laboratory result from a blood sample available and with usable data for the specified analysis for the specified time period. Here, 'number analyzed' = participants with available data for each specified row. | Posted | Count of Participants | Participants | Up to 14 days prior to their study visit at Day 1 |
|
|
|
| Secondary | Number of Participants in Each Geo-referenced Segment | The number of participants was summarized by: center number/ country [BF, SN, TZ, KE, GH, MA]/ city followed by the segment ID. Positioning of the participant's residence was attributed to a segment with a unique ID from the grid referencing study area map in which the participant resided; where necessary, grouping small geographically proximate villages so that each segment had at least 10 study participants to avoid personally identifiable information (PII), and proceeding as far as geographically appropriate. | The analysis was performed on the ATP Cohort which included all participants who met the eligibility criteria, adhered to the procedures defined in the protocol, had no elimination criteria during the study, had at least one laboratory result from a blood sample available and with usable data for the specified analysis at the specified time point. Here, 'number analyzed' = participants with available data for each specified row. | Posted | Count of Participants | Participants | At Day 1 (survey completion visit) |
|
|
|
| Secondary | Number of Participants Experiencing Malaria Risk Factors Categorized by the Number of Participants Living in the Same House (by Parasite Density) | Participants were categorized by the number of people living in the same house relative to enrolled participants as follows: less than of equal to (<=) 3 per 1 enrolled (LE 3/1), 4-5 per 1 (4-5/1), more than (>) 5 per 1 (GT 5/1); <=3 per 2 enrolled (LE 3/2), 4-5 per 2 (4-5/2), >5 per 2 (GT 5/2); <=3 per 3 enrolled (LE 3/3), 4-5 per 3 (4-5/3), >5 per 3 (GT 5/3); 4-5 per more than 3 enrolled (4-5/GT 3), >5 per more than 3 enrolled (GT 5/GT 3). Participants were also categorized by parasite density: low (<2500 parasites/μL), medium (2500-9999/μL), high (10000-19999/μL), very high (>=20000/μL), negative, and missing. | The analysis was performed on the ATP Cohort which included all participants who met the eligibility criteria, adhered to the procedures defined in the protocol, had no elimination criteria during the study, had at least one laboratory result from a blood sample available and with usable data for the specified analysis at the specified time point. Here, 'number analyzed' = participants with available data for each specified row. | Posted | Count of Participants | Participants | At Day 1 (survey completion visit) |
|
|
|
| Secondary | Number of Participants Experiencing Malaria Risk Categorized by Location (by Parasite Density) | Participants were categorized by location as follows: situation area (rural, urban, semi-rural) and type of location (large city, small city, town, countryside). Participants were also categorized by parasite density: low (<2500 parasites/μL), medium (2500-9999/μL), high (10000-19999/μL), very high (>=20000/μL), negative, and missing. | The analysis was performed on the ATP Cohort which included all participants who met the eligibility criteria, adhered to the procedures defined in the protocol, had no elimination criteria during the study, had at least one laboratory result from a blood sample available and with usable data for the specified analysis at the specified time point. Here, 'number analyzed' = participants with available data for each specified row. | Posted | Count of Participants | Participants | At Day 1 (survey completion visit) |
|
|
|
| Secondary | Number of Participants Experiencing Malaria Risk Factors Categorized by House Information (by Parasite Density) | Participants were categorized by house characteristics as follows: wall material (mud, brick, cement/plaster, clay, other), floor material (natural, rudimentary, vinyl/asphalt strips, parquet/polished wood, ceramic tiles, cement, carpet, clay, other), roof type (iron sheet, tiles, clay, other), window type (closed, open, no window, partially open, other), presence of nets (not present, present on all windows, present on some windows, other, missing), main drinking water source (closed, open), whether the open source was in the compound (yes, no, not available [NA]), and presence or absence of electricity. Participants were also categorized by parasite density: low (<2500 parasites/μL), medium (2500-9999/μL), high (10000-19999/μL), very high (>=20000/μL), negative, and missing. | The analysis was performed on the ATP Cohort which included all participants who met the eligibility criteria, adhered to the procedures defined in the protocol, had no elimination criteria during the study, had at least one laboratory result from a blood sample available and with usable data for the specified analysis at the specified time point. Here, 'number analyzed' = participants with available data for each specified row. | Posted | Count of Participants | Participants | At Day 1 (survey completion visit) |
|
|
|
| Primary | Number of Participants Infected With P. Falciparum by Joint Technical Expert Group (JTEG) Age Group | The number of participants was summarized by the JTEG age group (0.5-4Y and 5-9Y) by center number/ country [BF, SN, TZ, KE, GH, MA]/ city. UNEXP sites are the ones in which the RTS,S vaccine was not planned to be implemented during the course of the study however, vaccinated participants could still have been randomly selected in this population if vaccination happened in an EXP site, due to cross-site migration. The infection was identified using a blood smear slide and determined using microscopy. | The analysis was performed on the ATP Cohort which included all participants who met the eligibility criteria, adhered to the procedures defined in the protocol, had no elimination criteria during the study, had at least one laboratory result from a blood sample available and with usable data for the specified analysis at the specified time point. Here, 'number analyzed' = participants with available data for each specified row. | Posted | Count of Participants | Participants | At Day 1 (survey completion visit) |
|
|
|
| Primary | Number of Participants Using Malaria Control Interventions: Bednet Usage and Type of Bednet | The number of participants using malaria control interventions was summarized by: participants sleeping under a mosquito net the night before their visit, participants who have a new bednet (less than 1 year), participants who have a impregnated bednet (dipped in liquid to repel mosquitos after purchase), participants who have a pierced/torn bednet, participants with bednets classified by hole size (defined as holes big enough to let one finger go through) and number of holes (less than [<] 5 holes, more or equal [>=] to 5 holes, not applicable [NA] which is a participant who did not sleep under a bed net, missing confirmed [MC] which is a participant who slept under a mosquito net but who didn't answer to the question on holes). | The analysis was performed on the ATP Cohort which included all participants who met the eligibility criteria, adhered to the procedures defined in the protocol, had no elimination criteria during the study, had at least one laboratory result from a blood sample available and with usable data for the specified analysis at the specified time point. Here, 'number analyzed' = participants with available data for each specified row. | Posted | Count of Participants | Participants | At Day 1 (survey completion visit) |
|
|
|
| Primary | Number of Participants Using Malaria Control Interventions: Mosquito Coils, Insecticide Sprays, Commercial Repellants, Traditional Repellants and Indoor Residual Sprays | The number of participants using malaria control interventions was summarized by: mosquito coils, insecticide sprays, commercial repellants, traditional repellants and indoor residual sprays (in the past 12 months, 1 to 12 months, NA [the participant didn't use the residual spray], missing [participant used spray but didn't answer to how long ago]). | The analysis was performed on the ATP Cohort which included all participants who met the eligibility criteria, adhered to the procedures defined in the protocol, had no elimination criteria during the study, had at least one laboratory result from a blood sample available and with usable data for the specified analysis at the specified time point. Here, 'number analyzed' = participants with available data for each specified row. | Posted | Count of Participants | Participants | At Day 1 (survey completion visit) |
|
|
|
| 0 |
| 4,214 |
| 0 |
| 4,214 |
| 0 |
| 0 |
| EG001 | Survey 2 Group | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 2. | 0 | 4,204 | 0 | 4,204 | 0 | 0 |
| EG002 | Survey 3 Group | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 3. | 0 | 2,400 | 0 | 2,400 | 0 | 0 |
| EG003 | Survey 4 Group | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 4. | 0 | 3,003 | 0 | 3,003 | 0 | 0 |
| EG004 | Survey 5 Group | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 5. | 0 | 5,417 | 0 | 5,417 | 0 | 0 |
| EG005 | Survey 6 Group | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 6. | 0 | 5,991 | 0 | 5,991 | 0 | 0 |
| EG006 | Survey 7 Group | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 7. | 0 | 7,246 | 0 | 7,246 | 0 | 0 |
| EG007 | Survey 8 Group | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 8. | 0 | 7,220 | 0 | 7,220 | 0 | 0 |
| EG008 | Survey 9 Group | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 9. | 0 | 7,203 | 0 | 7,203 | 0 | 0 |
| EG009 | Survey 10 Group | Participants aged 6 months to <10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 10. | 0 | 7,202 | 0 | 7,202 | 0 | 0 |
GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.
| D000079426 |
| Vector Borne Diseases |
| D011677 | Punctures |
| D013514 | Surgical Procedures, Operative |
| D008919 | Investigative Techniques |
|
|
|
|
|
|
|
|
|
| Male |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 207079_BF_Sapone |
|
|
| 207080_SN_Niakhar |
|
|
| 207081_TZ_Korogwe |
|
|
| 207082_KE_Kombewa |
|
|
| 207083_GH_Kintampo |
|
|
| 207083_GH_Kintampo_EXP |
|
|
| 207083_GH_Kintampo_UNEXP |
|
|
| 207084_SN_Keur Soce |
|
|
| 228607_GH_Navrongo_EXP |
|
|
| 228607_GH_Navrongo_UNEXP |
|
|
| 233149_MA_Mangochi |
|
|
| 233150_MA_Chikwawa |
|
|
| 233149_MA_Monkey Bay |
|
|
| 233150_MA_St Monfort |
|
|
| 235578_KE_Bondo |
|
|
| 235578_KE_Gem |
|
|
| 235579_KE_Nyando |
|
|
| P. vivax |
|
| P. ovale |
|
| Measles [1st dose] |
|
|
| Where the participant was taken for treatment - Drug seller |
|
|
| Where the participant was taken for treatment - Pharmacy |
|
|
| Where the participant was taken for treatment - Private clinic |
|
|
| Where the participant was taken for treatment - Health center |
|
|
| Where the participant was taken for treatment - Hospital |
|
|
| Where the participant was taken for treatment - Other |
|
|
| Where the participant was taken for treatment - Not Applicable |
|
|
| Where the participant was taken for treatment - Missing |
|
|
| When the participant was taken for treatment - At onset |
|
|
| When the participant was taken for treatment - When participant did not improve |
|
|
| When the participant was taken for treatment - When participant got worse |
|
|
| When the participant was taken for treatment - Other |
|
|
| When the participant was taken for treatment - Not Applicable |
|
|
| When the participant was taken for treatment - Missing |
|
|
| What time the participant was taken for treatment - Same day |
|
|
| What time the participant was taken for treatment - Next day |
|
|
| What time the participant was taken for treatment - Two days later |
|
|
| What time the participant was taken for treatment - More than 2 days later |
|
|
| What time the participant was taken for treatment - Not Applicable |
|
|
| What time the participant was taken for treatment - Missing |
|
|
|
| 207078_BF_Nouna, ID-20707861 |
|
|
| 207078_BF_Nouna, ID-20707862 |
|
|
| 207078_BF_Nouna, ID-20707863 |
|
|
| 207078_BF_Nouna, ID-20707864 |
|
|
| 207078_BF_Nouna, ID-20707865 |
|
|
| 207078_BF_Nouna, ID-20707866 |
|
|
| 207078_BF_Nouna, ID-20707867 |
|
|
| 207078_BF_Nouna, ID-20707868 |
|
|
| 207078_BF_Nouna, ID-20707869 |
|
|
| 207078_BF_Nouna, ID-20707870 |
|
|
| 207078_BF_Nouna, ID-20707871 |
|
|
| 207078_BF_Nouna, ID-20707872 |
|
|
| 207078_BF_Nouna, ID-20707873 |
|
|
| 207079_BF_Sapone, ID-1 |
|
|
| 207079_BF_Sapone, ID-10 |
|
|
| 207079_BF_Sapone, ID-11 |
|
|
| 207079_BF_Sapone, ID-12 |
|
|
| 207079_BF_Sapone, ID-13 |
|
|
| 207079_BF_Sapone, ID-14 |
|
|
| 207079_BF_Sapone, ID-2 |
|
|
| 207079_BF_Sapone, ID-3 |
|
|
| 207079_BF_Sapone, ID-4 |
|
|
| 207079_BF_Sapone, ID-5 |
|
|
| 207079_BF_Sapone, ID-6 |
|
|
| 207079_BF_Sapone, ID-7 |
|
|
| 207079_BF_Sapone, ID-8 |
|
|
| 207079_BF_Sapone, ID-9 |
|
|
| 207080_SN_Niakhar, ID-1 |
|
|
| 207080_SN_Niakhar, ID-2 |
|
|
| 207080_SN_Niakhar, ID-3 |
|
|
| 207080_SN_Niakhar, ID-4 |
|
|
| 207080_SN_Niakhar, ID-5 |
|
|
| 207080_SN_Niakhar, ID-6 |
|
|
| 207080_SN_Niakhar, ID-7 |
|
|
| 207080_SN_Niakhar, ID-8 |
|
|
| 207080_SN_Niakhar, ID-9 |
|
|
| 207081_TZ_Korogwe, ID-1 |
|
|
| 207081_TZ_Korogwe, ID-2 |
|
|
| 207081_TZ_Korogwe, ID-3 |
|
|
| 207081_TZ_Korogwe, ID-4 |
|
|
| 207081_TZ_Korogwe, ID-5 |
|
|
| 207081_TZ_Korogwe, ID-6 |
|
|
| 207081_TZ_Korogwe, ID-7 |
|
|
| 207082_KE_Kombewa, ID-11 |
|
|
| 207082_KE_Kombewa, ID-12 |
|
|
| 207082_KE_Kombewa, ID-13 |
|
|
| 207082_KE_Kombewa, ID-14 |
|
|
| 207082_KE_Kombewa, ID-21 |
|
|
| 207082_KE_Kombewa, ID-22 |
|
|
| 207082_KE_Kombewa, ID-23 |
|
|
| 207082_KE_Kombewa, ID-24 |
|
|
| 207083_GH_Kintampo, ID-1 |
|
|
| 207083_GH_Kintampo, ID-2 |
|
|
| 207083_GH_Kintampo, ID-3 |
|
|
| 207084_SN_Keur Soce, ID-1 |
|
|
| 207084_SN_Keur Soce, ID-2 |
|
|
| 207084_SN_Keur Soce, ID-3 |
|
|
| 207084_SN_Keur Soce, ID-4 |
|
|
| 207083_GH_Kintampo_EXP, ID-1 |
|
|
| 207083_GH_Kintampo_EXP, ID-2 |
|
|
| 207083_GH_Kintampo_EXP, ID-3 |
|
|
| 207083_GH_Kintampo_UNEXP, ID-2070831 |
|
|
| 207083_GH_Kintampo_UNEXP, ID-2070832 |
|
|
| 207083_GH_Kintampo_UNEXP, ID-2070833 |
|
|
| 228607_GH_Navrongo_EXP, ID-2286071 |
|
|
| 228607_GH_Navrongo_EXP, ID-2286072 |
|
|
| 228607_GH_Navrongo_EXP, ID-2286073 |
|
|
| 228607_GH_Navrongo_EXP, ID-2286074 |
|
|
| 228607_GH_Navrongo_EXP, ID-2286075 |
|
|
| 228607_GH_Navrongo_EXP, ID-22860705 |
|
|
| 228607_GH_Navrongo_EXP, ID-22860712 |
|
|
| 228607_GH_Navrongo_UNEXP, ID-22860709 |
|
|
| 228607_GH_Navrongo_UNEXP, ID-2286071 |
|
|
| 228607_GH_Navrongo_UNEXP, ID-22860710 |
|
|
| 228607_GH_Navrongo_UNEXP, ID-22860711 |
|
|
| 228607_GH_Navrongo_UNEXP, ID-22860712 |
|
|
| 228607_GH_Navrongo_UNEXP, ID-22860713 |
|
|
| 228607_GH_Navrongo_UNEXP, ID-22860714 |
|
|
| 228607_GH_Navrongo_UNEXP, ID-2286072 |
|
|
| 228607_GH_Navrongo_UNEXP, ID-2286073 |
|
|
| 228607_GH_Navrongo_UNEXP, ID-2286074 |
|
|
| 228607_GH_Navrongo_UNEXP, ID-2286075 |
|
|
| 228607_GH_Navrongo_UNEXP, ID-2286076 |
|
|
| 228607_GH_Navrongo_UNEXP, ID-2286077 |
|
|
| 228607_GH_Navrongo_UNEXP, ID-2286078 |
|
|
| 228607_GH_Navrongo_UNEXP, ID-2286079 |
|
|
| 233149_MA_Mangochi, ID-23314902 |
|
|
| 233149_MA_Mangochi, ID-23314911 |
|
|
| 233149_MA_Mangochi, ID-23314912 |
|
|
| 233149_MA_Mangochi, ID-23314913 |
|
|
| 233149_MA_Mangochi, ID-23314921 |
|
|
| 233149_MA_Mangochi, ID-23314922 |
|
|
| 233149_MA_Monkey Bay, ID-23314911 |
|
|
| 233149_MA_Monkey Bay, ID-23314912 |
|
|
| 233149_MA_Monkey Bay, ID-23314921 |
|
|
| 233149_MA_Monkey Bay, ID-23314922 |
|
|
| 233149_MA_Monkey Bay, ID-23314913 |
|
|
| 233150_MA_Chikwawa, ID-23315006 |
|
|
| 233150_MA_Chikwawa, ID-23315007 |
|
|
| 233150_MA_Chikwawa, ID-23315008 |
|
|
| 233150_MA_Chikwawa, ID-23315010 |
|
|
| 233150_MA_Chikwawa, ID-23315011 |
|
|
| 233150_MA_Chikwawa, ID-23315012 |
|
|
| 233150_MA_Chikwawa, ID-23315001 |
|
|
| 233150_MA_Chikwawa, ID-23315005 |
|
|
| 233150_MA_Chikwawa, ID-23315003 |
|
|
| 233150_MA_St Monfort, ID-23315001 |
|
|
| 233150_MA_St Monfort, ID-23315002 |
|
|
| 233150_MA_St Monfort, ID-23315003 |
|
|
| 233150_MA_St Monfort, ID-23315005 |
|
|
| 233150_MA_St Monfort, ID-23315010 |
|
|
| 233150_MA_St Monfort, ID-23315011 |
|
|
| 235578_KE_Bondo, ID-23557801 |
|
|
| 235578_KE_Bondo, ID-23557802 |
|
|
| 235578_KE_Bondo, ID-23557803 |
|
|
| 235578_KE_Bondo, ID-23557804 |
|
|
| 235578_KE_Bondo, ID-23557805 |
|
|
| 235578_KE_Bondo, ID-23557806 |
|
|
| 235578_KE_Gem, ID-23557801 |
|
|
| 235578_KE_Gem, ID-23557802 |
|
|
| 235578_KE_Gem, ID-23557803 |
|
|
| 235578_KE_Gem, ID-23557804 |
|
|
| 235578_KE_Gem, ID-23557805 |
|
|
| 235578_KE_Gem, ID-23557806 |
|
|
| 235579_KE_Nyando, ID-23557911 |
|
|
| 235579_KE_Nyando, ID-23557912 |
|
|
| 235579_KE_Nyando, ID-23557913 |
|
|
| 235579_KE_Nyando, ID-23557914 |
|
|
| 235579_KE_Nyando, ID-23557915 |
|
|
| 235579_KE_Nyando, ID-23557916 |
|
|
| 235579_KE_Nyando, ID-23557921 |
|
|
| 235579_KE_Nyando, ID-23557922 |
|
|
| 235579_KE_Nyando, ID-23557923 |
|
|
| 235579_KE_Nyando, ID-23557924 |
|
|
| 235579_KE_Nyando, ID-23557925 |
|
|
| 235579_KE_Nyando, ID-23557926 |
|
|
| 235579_KE_Nyando, ID-23557927 |
|
|
| 235579_KE_Nyando, ID-23557928 |
|
|
|
| LE 3/1, Medium parasite density |
|
|
| LE 3/1, High parasite density |
|
|
| LE 3/1, Very High parasite density |
|
|
| LE 3/1, Negative parasite density |
|
|
| LE 3/1, Missing |
|
|
| 4-5/1, Low parasite density |
|
|
| 4-5/1, Medium parasite density |
|
|
| 4-5/1, High parasite density |
|
|
| 4-5/1, Very High parasite density |
|
|
| 4-5/1, Negative parasite density |
|
|
| 4-5/1, Missing |
|
|
| GT 5/1, Low parasite density |
|
|
| GT 5/1, Medium parasite density |
|
|
| GT 5/1, High parasite density |
|
|
| GT 5/1, Very High parasite density |
|
|
| GT 5/1, Negative parasite density |
|
|
| GT 5/1, Missing |
|
|
| LE 3/2, Low parasite density |
|
|
| LE 3/2, Medium parasite density |
|
|
| LE 3/2, High parasite density |
|
|
| LE 3/2, Very High parasite density |
|
|
| LE 3/2, Negative parasite density |
|
|
| LE 3/2, Missing |
|
|
| 4-5/2, Low parasite density |
|
|
| 4-5/2, Medium parasite density |
|
|
| 4-5/2, High parasite density |
|
|
| 4-5/2, Very High parasite density |
|
|
| 4-5/2, Negative parasite density |
|
|
| 4-5/2, Missing |
|
|
| GT 5/2, Low parasite density |
|
|
| GT 5/2, Medium parasite density |
|
|
| GT 5/2, High parasite density |
|
|
| GT 5/2, Very High parasite density |
|
|
| GT 5/2, Negative parasite density |
|
|
| GT 5/2, Missing |
|
|
| LE 3/3, Low parasite density |
|
|
| LE 3/3, Medium parasite density |
|
|
| LE 3/3, High parasite density |
|
|
| LE 3/3, Very High parasite density |
|
|
| LE 3/3, Negative parasite density |
|
|
| LE 3/3, Missing |
|
|
| 4-5/3, Low parasite density |
|
|
| 4-5/3, Medium parasite density |
|
|
| 4-5/3, High parasite density |
|
|
| 4-5/3, Very High parasite density |
|
|
| 4-5/3, Negative parasite density |
|
|
| 4-5/3, Missing |
|
|
| GT 5/3, Low parasite density |
|
|
| GT 5/3, Medium parasite density |
|
|
| GT 5/3, High parasite density |
|
|
| GT 5/3, Very High parasite density |
|
|
| GT 5/3, Negative parasite density |
|
|
| GT 5/3, Missing |
|
|
| 4-5/GT 3, Low parasite density |
|
|
| 4-5/GT 3, Medium parasite density |
|
|
| 4-5/GT 3, High parasite density |
|
|
| 4-5/GT 3, Very High parasite density |
|
|
| 4-5/GT 3, Negative parasite density |
|
|
| 4-5/GT 3, Missing |
|
|
| GT 5/GT 3, Low parasite density |
|
|
| GT 5/GT 3, Medium parasite density |
|
|
| GT 5/GT 3, High parasite density |
|
|
| GT 5/GT 3, Very High parasite density |
|
|
| GT 5/GT 3, Negative parasite density |
|
|
| GT 5/GT 3, Missing |
|
|
|
| Situation area, Rural, Medium parasite density |
|
|
| Situation area, Rural, High parasite density |
|
|
| Situation area, Rural, Very High parasite density |
|
|
| Situation area, Rural, Negative parasite density |
|
|
| Situation area, Rural, Missing |
|
|
| Situation area, Urban, Low parasite density |
|
|
| Situation area, Urban, Medium parasite density |
|
|
| Situation area, Urban, High parasite density |
|
|
| Situation area, Urban, Very High parasite density |
|
|
| Situation area, Urban, Negative parasite density |
|
|
| Situation area, Urban, Missing |
|
|
| Situation area, Semi-rural, Low parasite density |
|
|
| Situation area, Semi-rural, Medium parasite density |
|
|
| Situation area, Semi-rural, High parasite density |
|
|
| Situation area, Semi-rural, Very High parasite density |
|
|
| Situation area, Semi-rural, Negative parasite density |
|
|
| Situation area, Semi-rural, Missing |
|
|
| Type of location, Large city, Low parasite density |
|
|
| Type of location, Large city, Medium parasite density |
|
|
| Type of location, Large city, High parasite density |
|
|
| Type of location, Large city, Very High parasite density |
|
|
| Type of location, Large city, Negative parasite density |
|
|
| Type of location, Large city, Missing |
|
|
| Type of location, Small city, Low parasite density |
|
|
| Type of location, Small city, Medium parasite density |
|
|
| Type of location, Small city, High parasite density |
|
|
| Type of location, Small city, Very High parasite density |
|
|
| Type of location, Small city, Negative parasite density |
|
|
| Type of location, Small city, Missing |
|
|
| Type of location, Town, Low parasite density |
|
|
| Type of location, Town, Medium parasite density |
|
|
| Type of location, Town, High parasite density |
|
|
| Type of location, Town, Very High parasite density |
|
|
| Type of location, Town, Negative parasite density |
|
|
| Type of location, Town, Missing |
|
|
| Type of location, Countryside, Low parasite density |
|
|
| Type of location, Countryside, Medium parasite density |
|
|
| Type of location, Countryside, High parasite density |
|
|
| Type of location, Countryside, Very High parasite density |
|
|
| Type of location, Countryside, Negative parasite density |
|
|
| Type of location, Countryside, Missing |
|
|
|
| Main house construction material of Walls: Mud, Medium parasite density |
|
|
| Main house construction material of Walls: Mud, High parasite density |
|
|
| Main house construction material of Walls: Mud, Very High parasite density |
|
|
| Main house construction material of Walls: Mud, Negative parasite density |
|
|
| Main house construction material of Walls: Mud, missing |
|
|
| Main house construction material of Walls: Brick, low parasite density |
|
|
| Main house construction material of Walls: Brick, Medium parasite density |
|
|
| Main house construction material of Walls: Brick, High parasite density |
|
|
| Main house construction material of Walls: Brick, very high parasite density |
|
|
| Main house construction material of Walls: Brick, Negative parasite density |
|
|
| Main house construction material of Walls: Brick, missing |
|
|
| Main house construction material of Walls: Cement/Plaster, low parasite density |
|
|
| Main house construction material of Walls: Cement/Plaster, Medium parasite density |
|
|
| Main house construction material of Walls: Cement/Plaster, High parasite density |
|
|
| Main house construction material of Walls: Cement/Plaster, very high parasite density |
|
|
| Main house construction material of Walls: Cement/Plaster, Negative parasite density |
|
|
| Main house construction material of Walls: Cement/Plaster, missing |
|
|
| Main house construction material of Walls: Cement/Paint, low parasite density |
|
|
| Main house construction material of Walls: Cement/Paint, Medium parasite density |
|
|
| Main house construction material of Walls: Cement/Paint, High parasite density |
|
|
| Main house construction material of Walls: Cement/Paint, very high parasite density |
|
|
| Main house construction material of Walls: Cement/Paint, Negative parasite density |
|
|
| Main house construction material of Walls: Cement/Paint, missing |
|
|
| Main house construction material of Walls: Clay, Low parasite density |
|
|
| Main house construction material of Walls: Clay, medium parasite density |
|
|
| Main house construction material of Walls: Clay, high parasite density |
|
|
| Main house construction material of Walls: Clay, very high parasite density |
|
|
| Main house construction material of Walls: Clay, negative parasite density |
|
|
| Main house construction material of Walls: Clay, missing |
|
|
| Main house construction material of Walls: Other, low parasite density |
|
|
| Main house construction material of Walls: Other, medium parasite density |
|
|
| Main house construction material of Walls: Other, high parasite density |
|
|
| Main house construction material of Walls: Other, very high parasite density |
|
|
| Main house construction material of Walls: Other, negative parasite density |
|
|
| Main house construction material: Walls: Other, missing |
|
|
| Main house construction material of Floor: Natural floor, low parasite density |
|
|
| Main house construction material of Floor: Natural floor, medium parasite density |
|
|
| Main house construction material of Floor: Natural floor, high parasite density |
|
|
| Main house construction material of Floor: Natural floor, very high parasite density |
|
|
| Main house construction material of Floor: Natural floor, negative parasite density |
|
|
| Main house construction material of Floor: Natural floor, missing |
|
|
| Main house construction material of Floor: Rudimentary floor, low parasite density |
|
|
| Main house construction material of Floor: Rudimentary floor, medium parasite density |
|
|
| Main house construction material of Floor: Rudimentary floor, high parasite density |
|
|
| Main house construction material of Floor: Rudimentary floor, very high parasite density |
|
|
| Main house construction material of Floor: Rudimentary floor, negative parasite density |
|
|
| Main house construction material of Floor: Rudimentary floor, missing |
|
| Main house construction material of Floor: Vinyl or asphalt strips, low parasite density |
|
|
| Main house construction material of Floor: Vinyl or asphalt strips, medium parasite density |
|
|
| Main house construction material of Floor: Vinyl or asphalt strips, high parasite density |
|
|
| Main house construction material of Floor: Vinyl or asphalt strips, very high parasite density |
|
|
| Main house construction material of Floor: Vinyl or asphalt strips, negative parasite density |
|
|
| Main house construction material of Floor: Vinyl or asphalt strips, missing |
|
| Main house construction material of Floor: Parquet/ polished wood, low parasite density |
|
|
| Main house construction material of Floor: Parquet/ polished wood, medium parasite density |
|
|
| Main house construction material of Floor: Parquet/ polished wood, high parasite density |
|
|
| Main house construction material of Floor: Parquet/ polished wood, very high parasite density |
|
|
| Main house construction material of Floor: Parquet/ polished wood, negative parasite density |
|
|
| Main house construction material of Floor: Ceramic tiles, low parasite density |
|
|
| Main house construction material of Floor: Ceramic tiles, medium parasite density |
|
|
| Main house construction material of Floor: Ceramic tiles, high parasite density |
|
|
| Main house construction material of Floor: Ceramic tiles, very high parasite density |
|
|
| Main house construction material of Floor: Ceramic tiles, negative parasite density |
|
|
| Main house construction material of Floor: Ceramic tiles, missing |
|
|
| Main house construction material of Floor: Cement, low parasite density |
|
|
| Main house construction material of Floor: Cement, medium parasite density |
|
|
| Main house construction material of Floor: Cement, high parasite density |
|
|
| Main house construction material of Floor: Cement, very high parasite density |
|
|
| Main house construction material of Floor: Cement, negative parasite density |
|
|
| Main house construction material of Floor: Cement, missing |
|
|
| Main house construction material of Floor: Carpet, low parasite density |
|
|
| Main house construction material of Floor: Carpet, medium parasite density |
|
|
| Main house construction material of Floor: Carpet, high parasite density |
|
|
| Main house construction material of Floor: Carpet, very high parasite density |
|
|
| Main house construction material of Floor: Carpet, negative parasite density |
|
|
| Main house construction material of Floor: Carpet, missing |
|
|
| Main house construction material of Floor: Clay, low parasite density |
|
|
| Main house construction material of Floor: Clay, medium parasite density |
|
|
| Main house construction material of Floor: Clay, high parasite density |
|
|
| Main house construction material of Floor: Clay, very high parasite density |
|
|
| Main house construction material of Floor: Clay, negative parasite density |
|
|
| Main house construction material of Floor: Clay, missing |
|
|
| Main house construction material of Floor: Other, low parasite density |
|
|
| Main house construction material of Floor: Other, medium parasite density |
|
|
| Main house construction material of Floor: Other, high parasite density |
|
|
| Main house construction material of Floor: Other, very high parasite density |
|
|
| Main house construction material of Floor: Other, negative parasite density |
|
|
| Main house construction material of Floor: Other, missing |
|
|
| Main house construction material of Roof: Grass/Palm, low parasite density |
|
|
| Main house construction material of Roof: Grass/Palm, medium parasite density |
|
|
| Main house construction material of Roof: Grass/Palm, high parasite density |
|
|
| Main house construction material of Roof: Grass/Palm, very high parasite density |
|
|
| Main house construction material of Roof: Grass/Palm, negative parasite density |
|
|
| Main house construction material of Roof: Grass/Palm, missing |
|
|
| Main house construction material of Roof: Iron sheet, low parasite density |
|
|
| Main house construction material of Roof: Iron sheet, medium parasite density |
|
|
| Main house construction material of Roof: Iron sheet, high parasite density |
|
|
| Main house construction material of Roof: Iron sheet, very high parasite density |
|
|
| Main house construction material of Roof: Iron sheet, negative parasite density |
|
|
| Main house construction material of Roof: Iron sheet, missing |
|
|
| Main house construction material of Roof: Tiles, low parasite density |
|
|
| Main house construction material of Roof: Tiles, medium parasite density |
|
|
| Main house construction material of Roof: Tiles, high parasite density |
|
|
| Main house construction material of Roof: Tiles, very high parasite density |
|
|
| Main house construction material of Roof: Tiles, negative parasite density |
|
|
| Main house construction material of Roof: Tiles, missing |
|
|
| Main house construction material of Roof: Clay, low parasite density |
|
|
| Main house construction material of Roof: Clay, medium parasite density |
|
|
| Main house construction material of Roof: Clay, high parasite density |
|
|
| Main house construction material of Roof: Clay, very high parasite density |
|
|
| Main house construction material of Roof: Clay, negative parasite density |
|
|
| Main house construction material of Roof: Clay, missing |
|
|
| Main house construction material of Roof: Other, low parasite density |
|
|
| Main house construction material of Roof: Other, medium parasite density |
|
|
| Main house construction material of Roof: Other, high parasite density |
|
|
| Main house construction material of Roof: Other, very high parasite density |
|
|
| Main house construction material of Roof: Other, negative parasite density |
|
|
| Main house construction material of Roof: Other, missing |
|
|
| Main house construction material of Windows/eaves: Closed, low parasite density |
|
|
| Main house construction material of Windows/eaves: Closed, medium parasite density |
|
|
| Main house construction material of Windows/eaves: Closed, high parasite density |
|
|
| Main house construction material of Windows/eaves: Closed, very high parasite density |
|
|
| Main house construction material of Windows/eaves: Closed, negative parasite density |
|
|
| Main house construction material of Windows/eaves: Closed, missing |
|
|
| Main house construction material of Windows/eaves: No Windows, low parasite density |
|
|
| Main house construction material of Windows/eaves: No Windows, medium parasite density |
|
|
| Main house construction material of Windows/eaves: No Windows, high parasite density |
|
|
| Main house construction material of Windows/eaves: No Windows, very high parasite density |
|
|
| Main house construction material of Windows/eaves: No Windows, negative parasite density |
|
|
| Main house construction material of Windows/eaves: No Windows, missing |
|
|
| Main house construction material of Windows/eaves: Open, low parasite density |
|
|
| Main house construction material of Windows/eaves: Open, medium parasite density |
|
|
| Main house construction material of Windows/eaves: Open, high parasite density |
|
|
| Main house construction material of Windows/eaves: Open, very high parasite density |
|
|
| Main house construction material of Windows/eaves: Open, negative parasite density |
|
|
| Main house construction material of Windows/eaves: Open missing |
|
|
| Main house construction material of Windows/eaves: Partially open, low parasite density |
|
|
| Main house construction material of Windows/eaves: Partially open, medium parasite density |
|
|
| Main house construction material of Windows/eaves: Partially open, high parasite density |
|
|
| Main house construction material of Windows/eaves: Partially open, very high parasite density |
|
|
| Main house construction material of Windows/eaves: Partially open, negative parasite density |
|
|
| Main house construction material of Windows/eaves: Partially open, missing |
|
|
| Main house construction material of Windows/eaves: Other, low parasite density |
|
|
| Main house construction material of Windows/eaves: Other, medium parasite density |
|
|
| Main house construction material of Windows/eaves: Other, high parasite density |
|
|
| Main house construction material of Windows/eaves: Other, very high parasite density |
|
|
| Main house construction material of Windows/eaves: Other, negative parasite density |
|
|
| Main house construction material of Windows/eaves: Other, missing |
|
|
| Main house construction material of Nets: Nets not present, low parasite density |
|
|
| Main house construction material of Nets: Nets not present, medium parasite density |
|
|
| Main house construction material of Nets: Nets not present, high parasite density |
|
|
| Main house construction material of Nets: Nets not present, very high parasite density |
|
|
| Main house construction material of Nets: Nets not present, negative parasite density |
|
|
| Main house construction material of Nets: Nets not present, missing |
|
|
| Main house construction material of Nets: Nets present on all windows, low parasite density |
|
|
| Main house construction material of Nets: Nets present on all windows, medium parasite density |
|
|
| Main house construction material of Nets: Nets present on all windows, high parasite density |
|
|
| Main house construction material of Nets: Nets present on all windows, very high parasite density |
|
|
| Main house construction material of Nets: Nets present on all windows, negative parasite density |
|
|
| Main house construction material of Nets: Nets present on all windows, missing |
|
|
| Main house construction material of Nets: Nets present on some windows, low parasite density |
|
|
| Main house construction material of Nets: Nets present on some windows, medium parasite density |
|
|
| Main house construction material of Nets: Nets present on some windows, high parasite density |
|
|
| Main house construction material of Nets: Nets present on some windows, very high parasite density |
|
|
| Main house construction material of Nets: Nets present on some windows, negative parasite density |
|
|
| Main house construction material of Nets: Nets present on some windows, missing |
|
|
| Main house construction material of Nets: Other, low parasite density |
|
|
| Main house construction material of Nets: Other, medium parasite density |
|
|
| Main house construction material of Nets: Other, high parasite density |
|
|
| Main house construction material of Nets: Other, very high parasite density |
|
|
| Main house construction material of Nets: Other, negative parasite density |
|
|
| Main house construction material of Nets: Other, missing |
|
|
| Main house construction material of Nets: Missing, low parasite density |
|
|
| Main house construction material of Nets: Missing, medium parasite density |
|
|
| Main house construction material of Nets: Missing, high parasite density |
|
|
| Main house construction material of Nets: Missing, very high parasite density |
|
|
| Main house construction material of Nets: Missing, negative parasite density |
|
|
| Main house construction material of Nets: Missing, missing |
|
|
| Main source of the drinking water: Closed water source, low parasite density |
|
|
| Main source of the drinking water: Closed water source, medium parasite density |
|
|
| Main source of the drinking water: Closed water source, high parasite density |
|
|
| Main source of the drinking water: Closed water source, very high parasite density |
|
|
| Main source of the drinking water: Closed water source, negative parasite density |
|
|
| Main source of the drinking water: Closed water source, missing |
|
|
| Main source of the drinking water: Open water source, low parasite density |
|
|
| Main source of the drinking water: Open water source, medium parasite density |
|
|
| Main source of the drinking water: Open water source, high parasite density |
|
|
| Main source of the drinking water: Open water source, very high parasite density |
|
|
| Main source of the drinking water: Open water source, negative parasite density |
|
|
| Main source of the drinking water: Open water source, missing |
|
|
| The open source is in compound: Yes, low parasite density |
|
|
| The open source is in compound: Yes, medium parasite density |
|
|
| The open source is in compound: Yes, high parasite density |
|
|
| The open source is in compound: Yes, very high parasite density |
|
|
| The open source is in compound: Yes, negative parasite density |
|
|
| The open source is in compound: Yes, missing |
|
|
| The open source is in compound: No, low parasite density |
|
|
| The open source is in compound: No, medium parasite density |
|
|
| The open source is in compound: No, high parasite density |
|
|
| The open source is in compound: No, very high parasite density |
|
|
| The open source is in compound: No, negative parasite density |
|
|
| The open source is in compound: No, missing |
|
|
| The open source is in compound: NA, low parasite density |
|
|
| The open source is in compound: NA, medium parasite density |
|
|
| The open source is in compound: NA, high parasite density |
|
|
| The open source is in compound: NA, very high parasite density |
|
|
| The open source is in compound: NA, negative parasite density |
|
|
| The open source is in compound: NA, missing |
|
|
| Number of participants in houses with the presence of electricity, low parasite density |
|
|
| Number of participants in houses with the presence of electricity, medium parasite density |
|
|
| Number of participants in houses with the presence of electricity, high parasite density |
|
|
| Number of participants in houses with the presence of electricity, very high parasite density |
|
|
| Number of participants in houses with the presence of electricity, negative parasite density |
|
|
| Number of participants in houses with the presence of electricity, missing |
|
|
| Number of participants in houses with no presence of electricity, low parasite density |
|
|
| Number of participants in houses with no presence of electricity, medium parasite density |
|
|
| Number of participants in houses with no presence of electricity, high parasite density |
|
|
| Number of participants in houses with no presence of electricity, very high parasite density |
|
|
| Number of participants in houses with no presence of electricity, negative parasite density |
|
|
| Number of participants in houses with no presence of electricity, missing |
|
|
|
| 0.5-4Y, 207079_BF_Sapone |
|
|
| 0.5-4Y, 207080_SN_Niakhar |
|
|
| 0.5-4Y, 207081_TZ_Korogwe |
|
|
| 0.5-4Y, 207082_KE_Kombewa |
|
|
| 0.5-4Y, 207083_GH_Kintampo |
|
|
| 0 .5-4Y, 207083_GH_Kintampo_EXP |
|
|
| 0.5-4Y, 207083_GH_Kintampo_UNEXP |
|
|
| 0.5-4Y, 207084_SN_Keur Soce |
|
|
| 0 .5-4Y, 228607_GH_Navrongo_EXP |
|
|
| 0.5-4Y, 228607_GH_Navrongo_UNEXP |
|
|
| 0 .5-4Y, 233149_MA_Mangochi |
|
|
| 0 .5-4Y, 233149_MA_Monkey Bay |
|
|
| 0 .5-4Y, 233150_MA_Chikwawa |
|
|
| 0 .5-4Y, 233150_MA_St Monfort |
|
|
| 0 .5-4Y, 235578_KE_Bondo |
|
|
| 0 .5-4Y, 235578_KE_Gem |
|
|
| 0.5-4Y, 235579_KE_Nyando |
|
|
| 5-9Y, 207078_BF_Nouna |
|
|
| 5-9Y, 207079_BF_Sapone |
|
|
| 5-9Y, 207080_SN_Niakhar |
|
|
| 5-9Y, 207081_TZ_Korogwe |
|
|
| 5-9Y, 207082_KE_Kombewa |
|
|
| 5-9Y, 207083_GH_Kintampo |
|
|
| 5-9Y, 207083_GH_Kintampo_EXP |
|
|
| 5-9Y, 207083_GH_Kintampo_UNEXP |
|
|
| 5-9Y, 207084_SN_Keur Soce |
|
|
| 5-9Y, 228607_GH_Navrongo_EXP |
|
|
| 5-9Y, 228607_GH_Navrongo_UNEXP |
|
|
| 5-9Y, 233149_MA_Mangochi |
|
|
| 5-9Y, 233149_MA_Monkey Bay |
|
|
| 5-9Y, 233150_MA_Chikwawa |
|
|
| 5-9Y, 233150_MA_St Monfort |
|
|
| 5-9Y, 235578_KE_Bondo |
|
|
| 5-9Y, 235578_KE_Gem |
|
|
| 5-9Y, 235579_KE_Nyando |
|
|
|
| New bednet [less than 1 year] |
|
|
| Impregnated [dipped in liquid to repel mosquitos after purchase] Bednet |
|
|
| Pierced/torn Bednet |
|
|
| How many holes of size, Less than 5 |
|
|
| How many holes of size, More or equal to 5 |
|
|
| How many holes of size, NA |
|
|
| How many holes of size, MC |
|
|
|
| Use of Insecticide sprays |
|
|
| Use of Commercial Repellents |
|
|
| Use of Traditional Repellents |
|
|
| Use of indoor residual spray (IRS) in past 12 months |
|
|
| Use of IRS 1 month ago |
|
|
| Use of IRS 2 month ago |
|
|
| Use of IRS 3 month ago |
|
|
| Use of IRS 4 month ago |
|
|
| Use of IRS 5 month ago |
|
|
| Use of IRS 6 month ago |
|
|
| Use of IRS 7 month ago |
|
|
| Use of IRS 8 month ago |
|
|
| Use of IRS 9 month ago |
|
|
| Use of IRS 10 month ago |
|
|
| Use of IRS 11 month ago |
|
|
| Use of IRS 12 month ago |
|
|
| Use of IRS, NA |
|
|
| Missing |
|
|
| Female, Infected |
|
| Male, Not infected |
|
| Female, Not infected |
|
| Male, Not infected |
|
| Female, Not infected |
|
| Male, Not infected |
|
| Female, Not infected |
|
| Female, Infected |
|
| Male, Not infected |
|
| Female, Not infected |
|
| Male, Not infected |
|
| Female, Not infected |
|
| Female, Infected |
|
| Male, Not infected |
|
| Female, Not infected |
|
| Female, Infected |
|
| Male, Not infected |
|
| Female, Not infected |
|
| Male, Not infected |
|
| Female, Not infected |
|
| Female, Infected |
|
| Male, Not infected |
|
| Female, Not infected |
|
| Female, Infected |
|
| Male, Not infected |
|
| Female, Not infected |
|
| Female, Infected |
|
| Male, Not infected |
|
| Female, Not infected |
|
| Female, Infected |
|
| Male, Not infected |
|
| Female, Not infected |
|
| Female, Infected |
|
| Male, Not infected |
|
| Female, Not infected |
|
| Female, Infected |
|
| Male, Not infected |
|
| Female, Not infected |
|
| Female, Infected |
|
| Male, Not infected |
|
| Female, Not infected |
|
| Female, Infected |
|
| Male, Not infected |
|
| Female, Not infected |
|
| Female, Infected |
|
| Male, Not infected |
|
| Female, Not infected |
|